Status:
TERMINATED
Positron Emission Tomography-Computed Tomography (PET-CT) High-grade Glioma
Lead Sponsor:
Maastricht Radiation Oncology
Collaborating Sponsors:
Maastricht University Medical Center
Conditions:
Cerebral Astrocytoma, High Grade
Eligibility:
All Genders
19+ years
Brief Summary
The objectives of the trial are: * To determine the localisation within the primary tumor of the therapy resistant cells, before and during radiotherapy to determine a possible accurate boost volume....
Detailed Description
Patients harboring a primary intracerebral high grade tumor (WHO III- IV) have a median survival of six to 12 months. Combined chemoradiotherapy with temozolomide is now the standard of care since res...
Eligibility Criteria
Inclusion
- Histologically confirmed gliomas III - IV (glioblastoma, anaplastic astrocytoma, gliosarcoma) at primary diagnosis;
- WhO PFS \<= 2
- Tumours which do enhance on pre-operative imaging.
- Post-operative enough visible residual tumour on PET or status after biopsy only
- Age \>18 years
- Availability of deep fresh frozen tissue for molecular biologic evaluation - if possible
- Patient able to tolerate full course of conventional RT and follow serial scanning
- No previous radiotherapy to the head and neck and brain area.
- Prior neurosurgery within 6 weeks of treatment
- No previous chemotherapy before treatment of the glioma. Standard radiochemotherapy with temozolomide is not excluded
- No prior or concurrent medical condition which would make treatment difficult to complete. Medication with steroids is allowed.
- No incapacitated patients.
Exclusion
- Not histologically confirmed gliomas III - IV (glioblastoma, anaplastic astrocytoma, gliosarcoma) at primary diagnosis;
- WhO PFS \> 2
- No tumours which do enhance on pre-operative imaging.
- Post-operative not enough visible residual tumor on PET or status after biopsy only
- Age \<18 years
- No availability of deep fresh frozen tissue for molecular biologic evaluation
- Patient not able to tolerate full course of conventional RT and follow serial scanning
- Previous radiotherapy to the head and neck and brain area.
- Prior neurosurgery not within 6 weeks of treatment
- Previous chemotherapy before treatment of the glioma.
- Prior or concurrent medical condition which would make treatment difficult to complete.
- Incapacitated patients.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00643591
Start Date
June 1 2008
End Date
June 1 2010
Last Update
April 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht Radiation Oncology
Maastricht, Netherlands, 6202 AZ